Antazoline in Comparison to Propafenone in Pharmacological Cardioversion of Atrial Fibrillation.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 105 participants.
Also called NCT05720572
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 105 participants
- Sponsor
- Centre of Postgraduate Medical Education
- Registry
-
NCT05720572
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Poland
- Registry status
- Unknown status
Technical summary
Registry record NCT05720572. Randomized; triple masking; primary purpose treatment. Start 2019-09-01 (actual); primary completion 2025-09-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Antazoline in Comparison to Propafenone in Pharmacological Cardioversion of Atrial Fibrillation.
- Acronym
- AnProAF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Antazoline
- Intervention (Drug)
- Propafenone
- Lead sponsor
- Centre of Postgraduate Medical Education
Record details
- Record id
cardio:ct-nct05720572- Content hash
bbdebeb266020c413d3ccecd11da945f304274beb29eb82556eee01082d19c80